Please login to the form below

Not currently logged in
Email:
Password:

Deltyba

This page shows the latest Deltyba news and features for those working in and with pharma, biotech and healthcare.

Study shows Otsuka's TB drug works even in worst cases

Study shows Otsuka's TB drug works even in worst cases

Otsuka's recently-approved tuberculosis therapy Deltyba is effective even in complicated infections caused by extensively drug-resistant (XDR) strains of the bacterium, says a new study. ... Deltyba was approved for marketing last year in Europe, joining

Latest news

  • R&D productivity takes off R&D productivity takes off

    Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a

  • Otsuka wins approval for TB drug Deltyba Otsuka wins approval for TB drug Deltyba

    Otsuka wins approval for TB drug Deltyba. Second drug approved by EC in 2014 for multidrug resistant tuberculosis. ... Otsuka challenged this recommendation, and the CHMP later recommended Deltyba after a re-examination of the information supplied by

  • J&J gets EU green light for novel TB drug J&J gets EU green light for novel TB drug

    While wholly novel drugs to treat multidrug-resistant TB have been thin on the ground, last year saw a brace of new therapies approved in the EU, namely Otsuka's Deltyba

  • EMA to expand orphan drug HTA collaboration EMA to expand orphan drug HTA collaboration

    Deltyba and Lucane Pharma's Lucane both for multi-drug resistant tuberculosis.

  • Cell wall inhibitors for bacterial infections Cell wall inhibitors for bacterial infections

    The nitro-dihydroimidazo-oxazole derivative Delamanid (Deltyba; Otsuka Pharmaceutical) inhibits mycolic acid synthesis and thus the formation of the mycobacterial cell envelope.

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics